Alpha Teknova, Inc.
No enriched coverage for $TKNO in the last 7 days.
No SEC Form 4 filings for $TKNO in the last 30 days.
See all $TKNO insider activity →Alpha Teknova, Inc. (TKNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Teknova Announces Proposed Public Offering of Common Stock HOLLISTER, CA – October 20, 2026 – Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, a
Alpha Teknova (NASDAQ: TKNO) shares fell 22.3% after announcing a public offering of common stock, with proceeds for general corporate purposes. Preliminary Q3 2026 revenue is estimated at $12.5M-$12.7M, above consensus, with improved gross margins and adjusted EBITDA. The company reported $16.6M in cash and short-term investments as of September 30, 2026.
Alpha Teknova (TKNO) reported preliminary Q3 results, estimating revenue up 19-21% YoY and gross margin up 500-700 bps. Adjusted EBITDA is expected to improve by at least 25% YoY, though figures are unaudited and subject to review.
Recent TKNO coverage spans earnings, market movers and financial news.
The offering may dilute existing shares but provides capital for debt repayment and potential acquisitions.
The dilution from the public offering is likely to pressure the stock further.
Guidance beats expectations, likely prompting buying interest.
The DMF filing provides regulatory validation for PluriFreeze, likely supporting future sales to cell‑therapy developers and improving market perception of Teknova's product pipeline.
Price surge reflects modest revenue growth and new product launch.
AlphAI scores every news story that mentions TKNO with an AI model for sentiment and relevance, and aggregates insider trades from Alpha Teknova, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Alpha Teknova, Inc. (TKNO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Teknova Announces Proposed Public Offering of Common Stock HOLLISTER, CA – October 20, 2026 – Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, a
2 min readAlpha Teknova (NASDAQ: TKNO) shares fell 22.3% after announcing a public offering of common stock, with proceeds for general corporate purposes. Preliminary Q3 2026 revenue is estimated at $12.5M-$12.7M, above consensus, with improved gross margins and adjusted EBITDA. The company reported $16.6M in cash and short-term investments as of September 30, 2026.
2 min readAlpha Teknova (TKNO) reported preliminary Q3 results, estimating revenue up 19-21% YoY and gross margin up 500-700 bps. Adjusted EBITDA is expected to improve by at least 25% YoY, though figures are unaudited and subject to review.
1 min readTeknova (TKNO) and Pluristyx announced the completion of a Type II Drug Master File (DMF) for PluriFreeze, a cryopreservation system, for FDA submission. The DMF supports drug makers in clinical development and manufacturing. Teknova is the exclusive U.S. and Canada distributor of PluriFreeze, which is designed for scalable manufacturing of cell-based products.
2 min readFour biotech stocks reached 52-week highs on September 23, 2026. Alpha Teknova (TKNO) hit $9.35, reporting Q2 revenue of $12.2M. Moderna (MRNA) reached $192.31 after positive clinical trial data. AtriCure (ATRC) hit $65.48 with Q2 revenue of $153.6M. Illumina (ILMN) climbed to $256.17, reporting Q2 revenue of $1.59B.
2 min readOmeros (OMER) +13%, Alpha Teknova (TKNO) +5%, BioLife (BLFS) +6%, Schrodinger (SDGR) +4%, and InfuSystem (INFU) +2% hit 52-week highs. OMER reported $32.2M Q2 sales for YARTEMIS. TKNO launched Fill-Tek, with Q2 revenue up 18%. BLFS to be acquired by Repligen (RGEN) for $1.5B, Q2 revenue up 21%. SDGR co-founded Tectora. INFU Q2 revenue $36.9M, up 2.6%.
2 min readAlpha Teknova (TKNO) launched Fill-Tek, a system for custom single-use bag filling, offering flexibility in sizes, quantities, and testing. The system supports 250 mL to 200 L bags and is available immediately. TKNO's stock closed at $7.11, up 3.04%, and is at $7.50 in pre-market trading.
2 min readAlpha Teknova (NASDAQ: TKNO) raised its outlook after reporting record Q2 revenue. The company expects to become adjusted EBITDA-positive in 2027 with revenue between $52M and $57M. Key growth drivers include customer progression to higher-value products and increased biopharma funding. Teknova also plans to invest in commercial capabilities and evaluate bolt-on acquisitions.
2 min readA roundup of Wall Street analyst actions includes UBS upgrading Jabil to Buy, initiating Lincoln Electric and Century Aluminum with price targets, and Bernstein initiating PDF Solutions. JPMorgan reiterates Nvidia overweight and raises CoreWeave to $110. Other changes include Loop lowering Apple to $340, Truist upgrading Best Buy to $95, and Argus upgrading Boeing to buy.
3 min readConestoga Capital Advisors’ Q2 2026 investor letter highlighted a shift toward small caps, citing Russell 2000 and Russell 2000 Growth gains. The letter said Alpha Teknova (NASDAQ:TKNO) was a top contributor, with shares at $6.53 on Aug. 6, 2026, and Clinical Solutions revenue up 85%, supported by improving biotech funding and customer activity.
6 min read
